Briquilimab is under clinical development by Jasper Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Briquilimab’s likelihood of approval (LoA) and phase transition for Severe Combined Immune Deficiency (SCID) took place on 19 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Briquilimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Briquilimab overview

Briquilimab (AMG-191) is under development for the treatment of fanconi anemia,  myelodysplastic syndrome, severe combined immunodeficiency, acute myeloid leukemia, sickle cell disease, chronic granulomatous disease (CGD) and Gaucher disease type 1. The drug candidate acts by targeting stem cell growth factor receptor Kit. It is a humanized anti-c-Kit monoclonal antibody. It is administered through intravenous route. It was also under development for the treatment of inflammatory diseases such as idiopathic pulmonary fibrosis (IPF).

Jasper Therapeutics overview

Jasper Therapeutics focuses on development and commercialization of hematopoietic stem cell transplants. It develops and commercializes stem cell engineering for expanded use of stem cell transplantation. The company pipeline products are JSP191 is in clinical development that clears hematopoietic stem cells from bone marrow. It also engineered hematopoietic stem cells(eHSCs) platform to address the limitations of transplant grafts and unlock the potential of stem cells. Jasper Therapeutics is headquartered in ReedWood, California, The US.

Quick View Briquilimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Briquilimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genetic Disorders
  • Hematological Disorders
  • Immunology
  • Oncology
  • Respiratory
Key Developers
  • Sponsor Company: Jasper Therapeutics
  • Originator: Amgen
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.